Peak Bio (PKBOW) Stock Analysis

What Peak Bio does

Peak Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing therapeutic solutions for significant unmet medical requirements within the fields of oncology and inflammation. The company leverages its proprietary toxin, PH-1 (also referred to as Thailanstatin), a spliceosome modulator, to engineer its initial suite of innovative Antibody-Drug Conjugate (ADC) product candidates, specifically aimed at addressing critical gaps for cancer patients. Its foremost experimental therapy, PHP-303, a small molecule, is poised to enter a Phase II dose clinical study for the rare genetic condition, Alpha1 anti-trypsin deficiency (AATD). Peak Bio is situated in Palo Alto, California.

Key metrics

ETFs linked to PKBOW

Broad-market and Healthcare sector ETFs an investor holding Peak Bio is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PKBOW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Peak Bio?

Peak Bio trades under the ticker PKBOW on NASDAQ.

Which exchange is PKBOW listed on?

PKBOW is listed on NASDAQ.

What sector does Peak Bio operate in?

Peak Bio is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PKBOW in a portfolio?

PortView shows PKBOW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.